Fig. 1
Overall profile of dataset. a Comparison of Foundation Medicine (FM) Inc. dataset in the present study versus a benchmark group of publicly available data (PAD) for colorectal cancer (CRC) published by Memorial Sloan-Kettering (MSK)24, the Dana Farber Cancer Institute (DFCI)23, the Genomics Evidence Neoplasia Information Exchange (GENIE)25, and The Cancer Genome Atlas (TCGA); population characteristics are also compared to overall population reported in SEER (Surveillance, Epidemiology, and End Results)1. b Flowchart and analysis tree for populations defined by FM as high level of microsatellite instability (MSI-H) or microsatellite stable (MSS), or with known tumor mutation burden (TMB); generation of MSI-H/high TMB (MT-H) and MSI-H/low TMB (MT-L) analysis cohorts. c–e Frequency of MT-H tumors based on parameters of gender (Fe, female or Ma, male) as a factor of age (<40 or ≥40 years) (c), or primary tumor site (Co, colon or Re, rectum) (d); or in combined genders, based on age and tumor site (e). Error bars, 95% confidence intervals. Statistical significance is denoted by ***p < 0.005
